CStone's PD-L1 Candidate Shows Positive Results for Lymphoma

00:22 EST 9 Nov 2019 | ChinaBio Today

Suzhou's CStone Pharma released positive results from a China Phase II trial of its PD-L1 candidate (CS1001) as a monotherapy in relapsed or refractory extranodal natural killer/T-cell lymphoma (rr-ENKTL). CS1001 produced an overall response rate of 41%, a complete and durable response rate of 32% and a benign safety profile. The company says studies have shown links between Epstein-Barr virus (EBV) infection and ENKTL. EBV infection induces immune tolerance by upgrading PD-L1 expression in tumor cells, promoting tumor growth. CStone is developing a pipeline of 15 oncology drug candidates. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

Original Article: CStone's PD-L1 Candidate Shows Positive Results for Lymphoma


More From BioPortfolio on "CStone's PD-L1 Candidate Shows Positive Results for Lymphoma"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...